Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status

HIV Clinical Trials

Volumn 12, Issue 1, 2011, Pages 1-8

  Perez Molina J A ^a   Suarez Lozano I ^b   Del Arco, A ^c   Teira, R ^b   Bachiller, P ^d   Pedrol, E ^e   Martinez Alfaro E ^f   Domingo, P ^g   Marino A ^h   Ribera, E ^g   Antela, A ⁱ   De Otero, J ^j   Navarro, V ^k   González García, Juan ^l  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Spanish VACH Cohort ^*  (Spain)

^c HOSPITAL COSTA DEL SOL   (Spain)

^d HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^e Hospital General de Albacete ^*  (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^g Hospital Clínico Universitario de Santiago de Compostela ^*  (Spain)

^h Universidad de La Coruña   (Spain)

ⁱ University Hospital of Santiago de Compostela   (Spain)

^j HOSPITAL DE MANACOR   (Spain)

^k University Hospital Vinalopó   (Spain)

^l HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

more..

Author keywords

HAART; HIV infection; immigrants; late initiation; na ve

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS EMTRICITABINE; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; EDUCATIONAL STATUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL CLASS; SPAIN; THERAPY DELAY;

EID: 79952557520     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1201-1     Document Type: Article

References (30)

1. Chadborn TR, Baster K, Delpech VC, et al. No time to wait: how many HIV-infected homosexual men are diag-nosed late and consequently die? (England and Wales, 1993-2002). AIDS. 2005;19(5):513-520. (Pubitemid 40515855)
2. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mor-tality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS. 2006;20(18):2371-2379. (Pubitemid 44789540)
3. Delpierre C, Lauwers-Cances V, Pugliese P, et al. Char-acteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health. 2008;18(3):345-347. (Pubitemid 351786632)
4. Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007;12(1):89-96. (Pubitemid 46340430)
5. Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res. 2009;7(2): 224-230.
6. Boyd AE, Murad S, O'Shea S, de Ruiter A, Watson C, Easterbrook PJ. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London. HIV Med. 2005;6(2):59-65. (Pubitemid 40425969)
7. Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindig-enous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr. 2004;36(4):943-950. (Pubitemid 38944090)
8. Burns FM, Imrie JY, Nazroo J, Johnson AM, Fenton KA. Why the(y) wait? Key informant understandings of factors contributing to late presentation and poor utilization of HIV health and social care services by African migrants in Britain. AIDS Care. 2007;19(1):102-108. (Pubitemid 44852415)
9. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. HIV Med. 2008;9 (Suppl 2):23-25. (Pubitemid 351819092)
10. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiret-roviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47(4):441-448. (Pubitemid 351366961)
11. Dray-Spira R, Spire B, Heard I, Lert F Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. AIDS. 2007;21(Suppl 1):S5-12.
12. Lanoy E, Mary-Krause M, Tattevin P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol. 2006;59(8):829-835.
13. Navaza B, Navarro M, Guionnet A, Perez-Molina J, Lopez-Velez R. Africa, blood, and HIV: overcoming cultural bar-riers regarding HIV blood testing. XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
14. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13(5): 675-685.
15. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differ-ences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc. 2009;12(1):11.
16. Egger M. Outcomes of ART in resource-limited and indus-trialized countries. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA, USA.
17. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4<200 cells/microL) with HIV infection. HIV Med. 2004. 5. 2. 93-98. (Pubitemid 38404662)
18. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-129. (Pubitemid 34786200)
19. Mussini C, Manzardo C, Johnson M, et al. Patients pre-senting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22(18):2461-2469.
20. Rockstroh JK, Gatell J, Landman R, Antinori A. Manage-ment of late-presenting patients with HIV infection. Antivir Ther. 2010;15(Suppl 1):25-30.
21. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447-1450. (Pubitemid 43948252)
22. Pérez-Molina J, Mora M, Suarez-Lozano I, et al. Do HIV-infected immigrants initiating HAART have poorer treat-ment-related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 Study. Curr HIV Res. 2010;8(7):521-530.
23. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563-608.
24. Department of Health and Human Services. Panel on Anti-retroviral Guidelines for Adults and Adolescents: guidelines for the use of antiretrovirals agents in HIV-1-infected adults and adolescents. Updated December 1 2009. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 10, 2010.
25. Street E, Curtis H, Sabin CA, Monteiro EF, Johnson MA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med. 2009;10(6):337-342.
26. Johnson M, Sabin C, Girardi E. Definition and epide-miology of late presentation in Europe. Antivir Ther. 2010;15(Suppl 1):3-8.
27. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/rito-navir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
28. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-1397.
29. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240.
30. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-929. (Pubitemid 30177052)